MediciNova Reports Q3 Loss, R&D Continues

MediciNova, a biopharmaceutical firm, reported a Q3 net loss of $3.1 million, or $0.06 per share, and revenue of $123,300. Despite the loss, the company remains committed to its research and development efforts, with future financial reports expected to provide more insights into their clinical trials and potential new drug approvals.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.